LA JOLLA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Immunosyn Corporation's (OTC Bulletin Board: IMYN) CEO, Stephen Ferrone, will make a presentation to brokers and financial institutions at the Financial Services Exchange (FSX) Investment Conference at the Pointe South Mountain Resort in Phoenix, AZ on Thursday, October 25, 2007.
Immunosyn has obtained exclusive worldwide marketing, sales and distribution rights to SF-1019 from its largest shareholder, Argyll Biotechnologies, LLC. Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. The company went public in January of this year and its stock will begin trading on Friday, October 26, 2007.
"Immunosyn is privileged to present to the elite group of brokers and dealers at FSX. We look forward to communicating our company's objectives and overview as well as to answering questions," noted Ferrone.
FSX is a premier investment conference organization attended by independent NASD broker/dealer firms. For more than 20 years, FSX has brought these firms together for the purpose of sharing information and showcasing investment opportunities.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board:
IMYN) plans to market and distribute life enhancing therapeutics.
Currently, the company has exclusive worldwide rights from its largest
shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute
SF-1019, a compound that was developed from extensive research into
Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has
initiated the process for regulatory approval of SF-1019 in several
countries and preparations for clinical
|SOURCE Immunosyn Corporation|
Copyright©2007 PR Newswire.
All rights reserved